Parkinson’s Disease is a severely debilitating disease with few remedies available. This company is working on treatments using an existing drug that can help with symptoms and its shares are on a tear.
Adhera Therapeutics, Inc. (OTCPK: ATRX) announced the execution of a definitive license agreement to license MLR-1019 (armesocarb) to develop a new therapeutic for Parkinson’s Disease. The drug candidate will specifically address movement and non-movement symptoms of Parkinson’s.
Armesocarb has been around for 50 years and was even sold as recent as 2008 for certain psychiatric and CNS (central nervous system) conditions. The compound has an existing documented safety profile.
All Penny Stocks has been keeping an eye this stock, alerting Pro members back in June on the potential upswing.
Shares were trading at $0.35, up an astounding 250% in mid-morning trade.
